ATE447943T1 - Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon - Google Patents

Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon

Info

Publication number
ATE447943T1
ATE447943T1 AT06739215T AT06739215T ATE447943T1 AT E447943 T1 ATE447943 T1 AT E447943T1 AT 06739215 T AT06739215 T AT 06739215T AT 06739215 T AT06739215 T AT 06739215T AT E447943 T1 ATE447943 T1 AT E447943T1
Authority
AT
Austria
Prior art keywords
bazedoxifen
desmethylvenlafaxine
combination product
combination
product
Prior art date
Application number
AT06739215T
Other languages
English (en)
Inventor
Syed Shah
Mahdi Fawzi
Christopher Diorio
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716648&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE447943(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE447943T1 publication Critical patent/ATE447943T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
AT06739215T 2005-03-31 2006-03-22 Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon ATE447943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66690205P 2005-03-31 2005-03-31
PCT/US2006/010335 WO2006104791A1 (en) 2005-03-31 2006-03-22 O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof

Publications (1)

Publication Number Publication Date
ATE447943T1 true ATE447943T1 (de) 2009-11-15

Family

ID=36716648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06739215T ATE447943T1 (de) 2005-03-31 2006-03-22 Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon

Country Status (22)

Country Link
US (2) US20060223791A1 (de)
EP (1) EP1863464B1 (de)
JP (1) JP2008534592A (de)
KR (1) KR20070116607A (de)
CN (1) CN101151026A (de)
AR (1) AR052955A1 (de)
AT (1) ATE447943T1 (de)
AU (1) AU2006229869A1 (de)
BR (1) BRPI0608754A2 (de)
CA (1) CA2601898A1 (de)
CR (1) CR9392A (de)
DE (1) DE602006010343D1 (de)
ES (1) ES2335919T3 (de)
GT (1) GT200600127A (de)
IL (1) IL185864A0 (de)
MX (1) MX2007012167A (de)
NO (1) NO20074559L (de)
PE (1) PE20061336A1 (de)
RU (1) RU2007132852A (de)
TW (1) TW200719883A (de)
WO (1) WO2006104791A1 (de)
ZA (1) ZA200708323B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005232640B2 (en) * 2004-04-08 2011-07-28 Wyeth Bazedoxifene acetate solid dispersion formulations
MX2008000680A (es) * 2005-07-15 2008-03-14 Wyeth Corp Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso.
US7595340B2 (en) * 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
US7687520B2 (en) * 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
AR064014A1 (es) * 2006-11-29 2009-03-04 Wyeth Corp Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
IN2010CN00695A (de) * 2007-07-12 2010-08-27 Reddys Lab Ltd Dr
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
MX2012010659A (es) * 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
EP2407467A1 (de) * 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
WO2012140577A1 (en) * 2011-04-12 2012-10-18 Lupin Limited Modified release pharmaceutical compositions of desvenlafaxine
WO2013182170A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
WO2002003975A2 (en) * 2000-07-06 2002-01-17 Wyeth Combinations of ssri and estrogenic agents
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
NZ539791A (en) * 2001-02-12 2006-11-30 Wyeth Corp Novel succinate salt of o-desmethyl-venlafaxine
KR20050010886A (ko) * 2002-06-13 2005-01-28 와이어쓰 바제독시펜 치료 방식
EP1711167A1 (de) * 2004-02-06 2006-10-18 Wyeth Mehrteilige o-desmethylvenlafaxin-salze und ihre verwendung
WO2007011619A2 (en) * 2005-07-15 2007-01-25 Wyeth Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate

Also Published As

Publication number Publication date
EP1863464A1 (de) 2007-12-12
KR20070116607A (ko) 2007-12-10
WO2006104791A1 (en) 2006-10-05
AU2006229869A1 (en) 2006-10-05
AR052955A1 (es) 2007-04-11
ES2335919T3 (es) 2010-04-06
TW200719883A (en) 2007-06-01
IL185864A0 (en) 2008-01-06
ZA200708323B (en) 2010-03-31
RU2007132852A (ru) 2009-05-10
US20100221445A1 (en) 2010-09-02
PE20061336A1 (es) 2006-12-27
EP1863464B1 (de) 2009-11-11
BRPI0608754A2 (pt) 2010-01-26
US20060223791A1 (en) 2006-10-05
CA2601898A1 (en) 2006-10-05
CN101151026A (zh) 2008-03-26
NO20074559L (no) 2007-12-27
GT200600127A (es) 2006-11-29
MX2007012167A (es) 2007-11-22
DE602006010343D1 (de) 2009-12-24
JP2008534592A (ja) 2008-08-28
CR9392A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
ATE447943T1 (de) Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
CY2017006I2 (el) Αερολυμενες φθοροκινολονες και χρησεις αυτων
ATE466925T1 (de) Duftverfahren und produkt
DE602006020061D1 (de) Mucin-glycoprotein und anwendung davon
DE602006007831D1 (de) N-alkylcarbonylaminosäureester und n-alkylcarbonylaminosäurelaktonverbindungen und anwendung davon
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DE602006014155D1 (de) Dehydringene und promotoren aus kaffee
ATE442368T1 (de) 3-amino-2-arylpropylazaindole und anwendungen davon
DE602006016137D1 (de) Harzzusammensetzungen und harzformkörper
DE602006007660D1 (de) Duroplastische Zusammensetzung und Herstellungsverfahren
DE602006016866D1 (de) Thermoplastharzzusammensetzung und produkt daraus
DE602006013874D1 (de) Wässrige emulsion und klebstofffzusammensetzung
DE602007011770D1 (de) Thermoplastharzzusammensetzung und formkörper daraus
ATE488514T1 (de) Piperidinverbindungen und anwendungen davon
DE602006002396D1 (de) Kosmetiktuchprodukt
DE602006003440D1 (de) Filmbildende zusammensetzungen aus acyclischen carbonaten und polyaminen
ATE423465T1 (de) Fungizide und bioregulatorische mischungen
ATE502682T1 (de) Zusammensetzung zur feuerbekämpfung und formulierungen aus dieser zusammensetzung
DE602006017883D1 (de) Pipd-papier und daraus hergestellte komponenten
ATE442042T1 (de) Fungizide und bioregulatorische mischungen
TWI371272B (en) Substituted propanamide derivatives and pharmaceutical compositions thereof
DE602006006777D1 (de) Zusammensetzung und damit zusammenhängender Prozess
EP1937292A4 (de) Auf lopap basierende pharmazeutische zusammensetzungen und ihre verwendungen
DE602006001128D1 (de) Alkylcycloheptylmethylcarbonate und Riechstoffkompositionen
DE602007011466D1 (de) Arylpiperazinderivate und anwendungen davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties